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Stimulation of erythropoietin in renal insufficiency by hypobaric
hypoxia
J. Quick, A. Eichenberger, and U. Binswanger
Section of Nephrology, University Hospital, Zurich, Switzerland
Abstract. Patients with renal anaemia show inad-
equate levels of immunoreactive erythropoietin (Epo)
related to the degree of anaemia. The purpose of our
study is to compare the degree of stimulation of Epo
by means of hypobaric hypoxia in normal controls
and patients with renal anaemia. Baseline Epo con-
centrations were found to be 11.1 +2.0 U/l in 10
healthy volunteers and 11.4 ±4.6 U/l in six patients
with renal anaemia. After exposure to hypobaric
hypoxia equivalent to 4560 m above sea level for a
duration of 3.5 h, we observed a significant increase
in serum Epo in healthy volunteers to 22.8 ±9.1 U/l
(P< 0.005), while there was no increase in patients
with renal anaemia: 12.3±5.2 U/l (/><0.2).
Our results show that in patients with renal anae-
mia serum Epo concentrations are comparable to
those of normal controls, but inadequate in view of
the concomitant degree of anaemia. Stimulation by
acute hypobaric hypoxia was not possible in patients
with renal insufficiency as opposed to normal con-
trols. From these data it can be concluded that either
Epo production is working at maximum capacity
under baseline conditions, or an additional hybobaric
stimulus is not able to influence a disturbed set point
of the oxygen sensor regulating Epo synthesis.
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Introduction
The first author to describe the coincidence between
chronic renal failure and anaemia was R. Bright more
than a hundred years ago. It was not until 1906 that
Carnot and Deflandre [1] assumed a humoral factor
to be responsible for the stimulation of erythropoiesis.
The chemical structure of this factor remained elusive
for many decades until Miyake et al. were able to
purify the glycoprotein erythropoietin (Epo) [2]. Since
Jacobs et al. [3] successfully cloned Epo in 1985, we
have come to know its exact chemical structure,
which contains 166 amino acids with a peptide
molecular weight of 18kDa and a carbohydrate
content with three N-glucosylation sites giving a total
molecular weight of 34 kDa.
Now Epo is recognized as the most significant
hormone for the regulation of the proliferation and
differentiation of erythroid precursors in the bone
marrow. In the adult, more than 90% of Epo is
produced in the kidney and less than 10% in the
liver. The exact Epo producing cell is not known at
present. There is, however, evidence that in the kid-
ney, Epo producing cells are inner cortical peritubular
interstitial cells [4].
The hormone takes part in a complex and not yet
fully understood feedback mechanism to regulate the
red blood cell population according to physiological
demands. The main stimuli for Epo production are
anaemia and hypoxic hypoxia. It is well established
that in individuals with non-renal anaemia, serum
Epo concentration is inversely correlated with the
haematocrit. In contrast, in patients with renal anae-
mia the serum Epo does not correspond to the degree
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of anaemia, suggesting that anaemia due to chronic
renal diseases is caused by relative Epo deficiency
[5-8].
Recombinant human Epo (rHuEpo) has been avail-
able for clinical use since 1988 and has been adminis-
tered successfully for the treatment of renal anaemia.
The present study was designed to determine the
possibility of stimulating endogenous Epo production
in a collective of patients suffering from renal anae-
mia. It has often been shown that in healthy subjects
a sojourn at high altitudes increases Epo concentra-
tions in blood and urine [9-16]. We chose to alter
the duration and degree of hypobaric hypoxia, extra-
polating from the data of Eckardt et al. [17] obtained
in normal individuals. We measured immunoreactive
serum Epo before and after exposure to hypobaric
hypoxia.
Subjects and methods
Patients
One female and nine male volunteers with a mean age of
33 years (range 28-49) were chosen to form a control
group. All laboratory parameters inclusive of haematocrit
and creatinine values were in the normal range. Six male
patients with a mean age of 47.3 years (range 29-69)
suffering from chronic renal failure and renal anaemia were
selected. Haematocrit was between 22.4 and 31.3%, haemo-
globin concentration between 7.5 and 10.3 g/dl, and creatin-
ine values were between 545 and 1264 nmol/1. Before
decompression, we also measured other laboratory para-
meters such as serum urea, serum potassium, calcium,
inorganic phosphate, alkaline phosphatase, serum iron,
transferrin, ferritin, number of erythrocytes, reticulocytes,
leukocytes, thrombocytes, total protein, and immunoreac-
tive serum Epo concentration. No patients had parathyro-
idectomy; serum immunoreactive parathyroid hormone was
not measured. Four patients were in predialysis stage, two
patients began haemodialysis immediately preceding our
study. None of them had been treated with rHuEpo or
were anephric. The diagnoses were glomerulonephritis (3
patients), reflux nephropathy (2 patients) and diabetic
nephropathy (1 patient). See Table 1.
Protocol
The procedure was explained and well understood by all
patients who agreed to join the study. The experiment was
performed at the Center for Hyperbaric Treatment and
Diving Research at the University Hospital Zurich, Switzer-
land, with an altitude simulation unit for altitudes up to
10000 m. The patients were decompressed over a period
of '. 5 ir.ir. from an atmospheric pressure of 722 mmHg
(corresponding to an altitude of 470 m above sea level) to
427 mmHg (corresponding to an altitude of 4569 m above
sea level). All subjects remained at this decompression for
3.5 h followed by the recompressior., v.hxh lasted between
20 and 30 min. The partial pressure of oxygen was held
constant z\ 23%. Temperature v.as varied tc afford comfort.
Blood samples were obtained by puncture of the antecubital
Table 1. Laboratory parameters and diagnoses for the six patients
with renal anaemia
Patient no.
Baseline Epo (U 1)
Diagnosis
Urea (mmol 1)
Creatinine (umol 1)
Total protein (g 1)
Potassium (mmol 1)
Calcium (mmol 1)
Phosphorus (mmol 1)
Alk. Ph. (U 1)
Fe (umol 1)
Transferrin (umol 1)
Ferritin (pgJ)
Hb (g dl)
Erythrocytes (million, ul)
Hct (%)
Reticulocytes (%>)
Leukocytes (mill ul)
Thrombocytes (mill/ul)
1*
11.2
RN
30.7
1264
71
4.2
1.86
1.85
164
8.6
32
50.1
7.5
2.52
24.0
13
7.66
222
2
14.4
RN
39.5
722
69
5.6
2.32
1.41
60
10.7
19
103
9.4
3.30
28.5
24
8.6
288
3
15.8
GN
31.0
615
71
4.0
2.17
2.22
61
10.6
27
118
7.7
2.36
22.4
19
6.3
213
4*
5.0
GN
31.4
901
69
4.3
2.22
2.04
96
17.1
29
188
8.5
2.85
24.9
25
6.4
263
5
6.8
DN
31.1
545
82
4.1
2.31
1.47
82
14.4
31
24.0
9.4
3.16
28.5
5
6.4
308
6
15.2
GN
31.8
760
78
5.2
2.20
1.47
78
11.9
31
133
10.3
3.48
31.3
17
7.4
189
GN, glomerulonephritis; RN, reflux nephropathy; DN, diabetic
nephropathy.
* Haemodialysis stage, all others were in predialysis stage.
vein. The first sample was drawn before entering the
chamber and included all serum parameters used to confirm
chronic renal failure and Epo. The second sample was
taken after 3.5 h sojourn at high altitude, the third sample
was taken 1 h after having left the chamber. Epo was
measured with a commercially available ELISA kit (Medag,
Hamburg, Germany) [18]. Blood samples were centrifuged
for 10 min at lOOOg and immediately stored at a temper-
ature of — 20'C until Epo analysis was completed. Duplic-
ate samples were analysed in the same assay. Statistical
analysis was performed using Wilcoxon's rank test for
paired and unpaired data as appropriate. Data are given
as mean±SD. All other chemical and haematological para-
meters were measured using autoanalyser and automatic
counter techniques respectively.
Results
Comparing baseline serum Epo concentrations
between healthy subjects and patients, no significant
difference was found. Healthy subjects' Epo values
ranged from 7.4 to 15.0 U/l with a mean and SD of
11.1+2.0; patients' Epo values ranged from 8 to
16 U/l with a mean and SD of 11.4 + 4.6 U/l (P=
0.45).
After a 3.5 h sojourn at high altitude we observed
a mean increase of serum Epo concentration in
healthy persons to 22.8±9.1 U I, showing a relative
mean increase of 101*55% (P<0.005, t = 4.6). See
Table 2. Serum Epo in patients showed a mean
increase to 12.3 ±5.2 U/l, which means a relative
mean increase of 7.5*14% (/ )<0.2), which is not
statistically significant. The range of relative increase
in serum Epo in healthy controls was from 50 to
1004
Table 2. Serum Epo levels for six
compared to baseline values
Patient no.
1
2
3
4
5
6
Mean
±SD
Control no
1
2
3
4
5
6
7
8
9
10
Mean
Baseline
Epo(a)
(U/l)
11.2
14.2
15.8
5.0
68
152
11.4
4 6
15.0
9.6
10.7
10.1
7.4
11.2
12.8
12.0
11.2
11.2
11 1
2.0
patients and 10 controls at
After 3.5 h
exposure(b)
(U/l)
13.8
12.8
15.8
5.4
6.8
19.0
123
52
37 5
20.8
20.6
19.2
15.4
18.8
42.0
18.8
17.0
178
22 8
9 1
baseline (a) and
Relative
change(ab)
(%)
+ 23
- I I
0
+ 8
0
+ 25
+ 7 5
14
+ 150
+ 116
+ 92
+ 90
+ 108
+ 68
+ 228
+ 57
+ 52
+ 50
+ 101
55
after 3.5 h of exposure (b)
1 h after
recompr.(c)
(U/l)
16.6
12.2
158
10.2
7.8
20 2
13.8
4.6
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with relative change (ab) as
Relative
change(ac)
(%)
+ 38
- 1 5
0
+ 104
+ 15
+ 33
+ 29
41
Serum Epo levels were also measured 1 h after leaving the chamber/recompression (c) in the patients only
228%. In contrast, the patients showed increases
from - 11 to 25%.
These results revealed a significant difference in
serum Epo after exposure to altitude between healthy
subjects and renal patients (P< 0.025). Patient num-
bers were too small to detect a difference between
dialysis and non-dialysis patients, nor did we find a
correlation between patient's haematocrit and serum
Epo before the exposure to hypobaric hypoxia. Indi-
ces of uraemia such as creatinine, urea, K, Ca, P,
and AP were not related to the Epo response either.
Taking into account serum Epo 1 h after having left
the decompression chamber, no statistically signific-
ant mean increase was found. Reasons for the great
range of relative change in serum Epo (from - 15 to
104%) could not be identified.
Discussion
To our knowledge this is the first study since Blum-
berg el al. in 1973 [19] and Chandra el al. in 1988
[20] involving the exposure of patients with chronic
renal diseases to acute hypobaric hypoxia under
controlled conditions. Blumberg exposed six uraemic
patients to an altitude of 3450 m and observed a
significant increase in Fe incorporation when testing
their sera in the polycythaemic mouse bioassay. Chan-
dra observed uraemic children during episodes of
acute hypoxic stress such as pulmonary oedema, acute
haemolysis, heart failure, and hypotension from sepsis
and found serum Epo concentrations during these
periods were tenfold higher than during steady-state
chronic renal failure.
In an earlier experiment (unpublished), we had
exposed six controls and 12 patients to an altitude
simulating an equivalent of 4000 m above sea level
for 1 h. Disappointingly, in this earlier study we did
not observe a significant change of serum Epo, either
in healthy controls or in the patients. We drew the
conclusion that the degree of stimulation was not
sufficient to activate Epo production. We decided
therefore to repeat these experiments with a more
severe degree of hypoxia. We chose an altitude of
4560 m above sea level to be sufficient yet tolerable
for a prolonged stay of 3.5 h taking into account the
severe anaemia of our patients.
Our present experiment design showed clearly the
adequacy of the hypobaric hypoxia stimulus resulting
in an increase in Epo by all healthy controls. There-
fore this degree of stimulation should be satisfactory
to reveal endogenous Epo production in renal failure.
The chief finding of our present study is that despite
the severity of our chosen stimulus we could not
demonstrate stimulation of augmented Epo in circula-
tion after 3.5 h exposure in our patients.
Since patients with chronic renal failure have sim-
ilar baseline Epo values and presumably production
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as normal controls, why can the Epo production not
be further stimulated as in the controls? These abnor-
mal findings ma> lead us to speculate about the actual
mechanism of the stimulus of the Epo producing
cells. Hypobaric hypoxia creates a reduced oxygen
partial pressure in all tissues, causing hyperventilation
and respiratory alkalosis. Existing studies on healthy
humans and laboratory animals show that hypoxia
of the tissue combined with alkalosis are accompanied
by Epo stimulation [12,16].
It is well known that in kidney failure, due to
bicarbonate loss and a lack of acid excretion, the
acid-base status is deranged into metabolic acidosis.
We tend to believe that the degree of hyperventilation
was not enough to create an alkalotic milieu as in
healthy persons, suggesting the necessity of both
parameters, tissue hypoxia and alkalosis, to result in
adequate stimulation of Epo production. There are
certainly other explanations for our findings. From
the morphopathological point of view all chronic
renal diseases lead to a reduced amount of functional
renal tissue, which may explain the lack of Epo
production, but maintaining a certain baseline Epo
level demonstrated in our study. Evidently, extrarenal
production (i.e. in the liver) seems not to be activated,
as has been shown in haemodialysis patients suffering
from an attack of hepatitis. It also remains unknown
to what extent the retention of uraemic substances,
especially the intermediate molecules such as hippuric
acid, xanthine, and hypoxanthine are responsible for
our inability to provoke Epo production. The effect
of the immunomodulatory peptides interleukin-1 (IL-
1), tumour necrosis factor-a (TNF-a) and interferon-
y (IFN-y) on the production of erythropoietin is still
unknown [21]. Other researchers [22] have identified
the importance of excretory renal function in the
regulation of Epo production. They found Epo pro-
duction to be related to the venous oxygen pressure
as an indicator of the renal oxygen supply as well as
the renal oxygen consumption. Reduced oxygen con-
sumption caused by acetazolamide, even in the pres-
ence of hypobaric hypoxia and a normal acid-base
balance, lead to reduced production of Epo.
It is yet to be proven whether a normalized acid-
base balance or adequate oxygen-consuming prox-
imal tubular system in renal insufficiency allows a
stimulation of endogenous erythropoietin. Despite
the findings of the above-mentioned researchers we
have gathered evidence to the contrary. With the data
and blood samples obtained by Krapf et al [23] we
were not able to demonstrate a correlation between
the acid-base disturbances and Epo production in
two sets of normal subjects, one with a normal acid-
base status, the other given ammonium chloride in
order to induce metabolic acidosis under the condi-
tion of prolonged altitude-induced hypobaric
hypoxia.
Our first experiment at 4000 m above sea level for
1 h showed no response in normals or patients. Our
current experiment at 4560 m for 3.5 h showed a
response in normals but not in patients. It remains
to be shown whether a more severe hypobaric hypoxia
than in our present protocol, which means higher
than 4560 m and/or longer than 3.5 h, would be
sufficient to stimulate Epo production even in end-
stage renal disease.
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